{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:45:11Z","timestamp":1793112311306,"version":"4.5.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chimeric antigen receptor (CAR) engineered cellular immunotherapy offers the potential for precise targeting and elimination of tumor cells, providing a tailored approach to cancer treatment. CAR-T cells demonstrate significant anti-tumor activity among these therapies. Nonetheless, these therapies may trigger adverse effects, including inflammatory and neurotoxic reactions during treatment. Recent efforts have been directed toward enhancing efficacy by optimizing CAR design or modulating its activity. Compared to CAR-T cells, CAR-engineered natural killer cells (CAR-NK) present notable advantages, including various sources and diminished toxicity, and are gaining recognition in clinical research. CAR-macrophages (CAR-M), while sharing antigenic domains similar to those of CAR-T cells, display superior capabilities in antigen presentation and tumor penetration. As a result, there is significant enthusiasm surrounding investigations into CAR-NK and CAR-M cell immunotherapies. This review explores the existing environment and obstacles associated with immunotherapies that utilize CAR-T, CAR-NK, and CAR-M cells to inspire novel pathways for forthcoming clinical applications.<\/jats:p>","DOI":"10.1186\/s40164-025-00683-y","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:54:05Z","timestamp":1751464445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Yong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"3","key":"683_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"683_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ans.16188","volume":"91","author":"SP Banting","year":"2021","unstructured":"Banting SP, Waters PS, Peacock O, Narasimhan V, Lynch AC, McCormick JJ, et al. Management of primary and metastatic malignant small bowel obstruction, operate or palliate. A systematic review. ANZ J Surg. 2021;91(3):282\u201390.","journal-title":"ANZ J Surg"},{"issue":"1","key":"683_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13244-021-01017-2","volume":"12","author":"D Albano","year":"2021","unstructured":"Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D, et al. Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe. Insights Imaging. 2021;12(1):76.","journal-title":"Insights Imaging"},{"issue":"1","key":"683_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"683_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86\u2013104.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"683_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-024-00576-6","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu J, Liu T, Sharma A, Jiang L, Wei F, Ren X, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Exp Hematol Oncol. 2024;13(1):105.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"MY Xu","year":"2024","unstructured":"Xu MY, Zeng N, Liu CQ, Sun JX, An Y, Zhang SH, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"683_CR8","first-page":"1814","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD Jr. Adv cancer Immunotherapies Cell. 2023;186(8):1814\u2013e141.","journal-title":"Adv cancer Immunotherapies Cell"},{"issue":"1","key":"683_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"683_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"683_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"683_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40164-024-00580-w","volume":"13","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu Q, Gao Z, Zhang H, Xie X, Li M. High-throughput screening for optimizing adoptive T cell therapies. Exp Hematol Oncol. 2024;13(1):113.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1615\/CritRevImmunol.v17.i1.40","volume":"17","author":"M Croft","year":"1997","unstructured":"Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol. 1997;17(1):89\u2013118.","journal-title":"Crit Rev Immunol"},{"issue":"4","key":"683_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"683_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12(1):86.","journal-title":"Biomark Res"},{"issue":"1","key":"683_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021;6(1):412.","journal-title":"Signal Transduct Target Ther"},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","volume":"4","author":"M Chmielewski","year":"2013","unstructured":"Chmielewski M, Hombach AA, Abken H. Antigen-Specific T-Cell activation independently of the MHC: chimeric antigen Receptor-Redirected T cells. Front Immunol. 2013;4:371.","journal-title":"Front Immunol"},{"issue":"8","key":"683_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol Ther. 2020;28(8):1783\u201394.","journal-title":"Mol Ther"},{"issue":"9","key":"683_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gt.2010.59","volume":"17","author":"P Neeson","year":"2010","unstructured":"Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8\u2009+\u2009T cells with effector and central memory-like phenotype. Gene Ther. 2010;17(9):1105\u201316.","journal-title":"Gene Ther"},{"issue":"355","key":"683_CR20","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8\u2009+\u2009and CD4\u2009+\u2009CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","journal-title":"Sci Transl Med"},{"key":"683_CR21","doi-asserted-by":"publisher","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","volume":"14","author":"J Luo","year":"2024","unstructured":"Luo J, Zhang X. Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol. 2024;14:1399544.","journal-title":"Front Oncol"},{"issue":"7","key":"683_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","volume":"26","author":"MA Nix","year":"2024","unstructured":"Nix MA, Wiita AP. Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments. Cytotherapy. 2024;26(7):729\u201338.","journal-title":"Cytotherapy"},{"issue":"2","key":"683_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/hyb.2008.0079","volume":"28","author":"SH Bakhtiari","year":"2009","unstructured":"Bakhtiari SH, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaee MJ. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybrid (Larchmt). 2009;28(2):85\u201392.","journal-title":"Hybrid (Larchmt)"},{"key":"683_CR24","first-page":"578128","volume":"2011","author":"N Pirooznia","year":"2011","unstructured":"Pirooznia N, Hasannia S, Taghdir M, Rahbarizadeh F, Eskandani M. The construction of chimeric T-Cell receptor with spacer base of modeling study of VHH and MUC1 interaction. J Biomed Biotechnol. 2011;2011:578128.","journal-title":"J Biomed Biotechnol"},{"key":"683_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","volume":"3","author":"JA Hammill","year":"2015","unstructured":"Hammill JA, VanSeggelen H, Helsen CW, Denisova GF, Evelegh C, Tantalo DG, et al. Designed Ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer. 2015;3:55.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"683_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.beha.2018.03.003","volume":"31","author":"JM Murad","year":"2018","unstructured":"Murad JM, Graber DJ, Sentman CL. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. Best Pract Res Clin Haematol. 2018;31(2):176\u201383.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"683_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7(1):100\u201312.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"683_CR28","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ymthe.2024.04.027","volume":"32","author":"JP Edwards","year":"2024","unstructured":"Edwards JP, Swers JS, Buonato JM, Zaritskaya L, Mu CJ, Gupta A, et al. Controlling CAR-T cell activity and specificity with synthetic SparX adapters. Mol Ther. 2024;32(6):1835\u201348.","journal-title":"Mol Ther"},{"issue":"7768","key":"683_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41586-019-1432-8","volume":"572","author":"RA Langan","year":"2019","unstructured":"Langan RA, Boyken SE, Ng AH, Samson JA, Dods G, Westbrook AM, et al. De Novo design of bioactive protein switches. Nature. 2019;572(7768):205\u201310.","journal-title":"Nature"},{"issue":"6382","key":"683_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"21","key":"683_CR31","doi-asserted-by":"publisher","first-page":"15688","DOI":"10.3390\/ijms242115688","volume":"24","author":"AC Uscanga-Palomeque","year":"2023","unstructured":"Uscanga-Palomeque AC, Ch\u00e1vez-Escamilla AK, Alvizo-B\u00e1ez CA, Saavedra-Alonso S, Terrazas-Armend\u00e1riz LD, Tamez-Guerra RS, et al. CAR-T cell therapy: from the shop to Cancer therapy. Int J Mol Sci. 2023;24(21):15688.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"683_CR32","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"683_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"WR Strohl","year":"2019","unstructured":"Strohl WR, Naso M. Bispecific T-Cell Redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill Cancer cells. Antibodies (Basel). 2019;8(3):41.","journal-title":"Antibodies (Basel)"},{"issue":"2","key":"683_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","volume":"26","author":"D Pettitt","year":"2018","unstructured":"Pettitt D, Arshad Z, Smith J, Stanic T, Holl\u00e4nder G, Brindley D. CAR-T cells: A systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther. 2018;26(2):342\u201353.","journal-title":"Mol Ther"},{"issue":"20 Pt 1","key":"683_CR35","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106\u201315.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"683_CR36","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"HM Finney","year":"1998","unstructured":"Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161(6):2791\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"683_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","volume":"172","author":"HM Finney","year":"2004","unstructured":"Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172(1):104\u201313.","journal-title":"J Immunol"},{"issue":"1","key":"683_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cells10010014","volume":"10","author":"M Pellegrino","year":"2020","unstructured":"Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E. Manipulating the metabolism to improve the efficacy of CAR T-Cell immunotherapy. Cells. 2020;10(1):14.","journal-title":"Cells"},{"issue":"13","key":"683_CR39","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, et al. Combined CD28 and 4-1BB costimulation potentiates Affinity-tuned chimeric antigen Receptor-engineered T cells. Clin Cancer Res. 2019;25(13):4014\u201325.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"683_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pul\u00e8","year":"2005","unstructured":"Pul\u00e8 MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933\u201341.","journal-title":"Mol Ther"},{"issue":"8","key":"683_CR41","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.3390\/ijms25084170","volume":"25","author":"J Rojas-Quintero","year":"2024","unstructured":"Rojas-Quintero J, D\u00edaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D, et al. Car T cells in solid tumors: overcoming Obstacles. Int J Mol Sci. 2024;25(8):4170.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"683_CR42","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelg\u00e5rd G, Wenthe J, L\u00f6vgren T, Amini RM, et al. A phase i\/iia trial using CD19-Targeted Third-Generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185\u201394.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"683_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Chen T, Li X, Zhang H, Li Y, Zhang S, et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):96.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"key":"683_CR45","doi-asserted-by":"publisher","first-page":"839783","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, et al. GMP-Compliant manufacturing of trucks: CAR T cells targeting GD(2) and releasing inducible IL-18. Front Immunol. 2022;13:839783.","journal-title":"Front Immunol"},{"issue":"3","key":"683_CR46","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"683_CR47","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: A novel bispecific chimeric antigen receptor for Cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"683_CR48","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126(10):3814\u201326.","journal-title":"J Clin Invest"},{"issue":"4","key":"683_CR49","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018;20(4):506\u201318.","journal-title":"Neuro Oncol"},{"issue":"1","key":"683_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","volume":"35","author":"K Fousek","year":"2021","unstructured":"Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021;35(1):75\u201389.","journal-title":"Leukemia"},{"issue":"215","key":"683_CR51","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.","journal-title":"Sci Transl Med"},{"issue":"4","key":"683_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 2023;13(4):829\u201343.","journal-title":"Cancer Discov"},{"issue":"6","key":"683_CR53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377\u201391.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"683_CR54","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial Antigen-Sensing circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"},{"issue":"12","key":"683_CR55","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.xcrm.2021.100457","volume":"2","author":"T Muliaditan","year":"2021","unstructured":"Muliaditan T, Halim L, Whilding LM, Draper B, Achkova DY, Kausar F, et al. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors. Cell Rep Med. 2021;2(12):100457.","journal-title":"Cell Rep Med"},{"issue":"12","key":"683_CR56","doi-asserted-by":"publisher","first-page":"e003176","DOI":"10.1136\/jitc-2021-003176","volume":"9","author":"S Zhao","year":"2021","unstructured":"Zhao S, Wang C, Lu P, Lou Y, Liu H, Wang T, et al. Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells. J Immunother Cancer. 2021;9(12):e003176.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"683_CR57","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426\u2013e3811.","journal-title":"Cell"},{"issue":"1","key":"683_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"683_CR59","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the Immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5270","key":"683_CR60","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1126\/science.272.5270.1939","volume":"272","author":"BL Levine","year":"1996","unstructured":"Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, et al. Antiviral effect and ex vivo CD4\u2009+\u2009T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science. 1996;272(5270):1939\u201343.","journal-title":"Science"},{"issue":"20","key":"683_CR61","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099\u2013102.","journal-title":"Blood"},{"issue":"4","key":"683_CR62","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/ijms22042150","volume":"22","author":"M Martino","year":"2021","unstructured":"Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A review of clinical outcomes of CAR T-Cell therapies for B-Acute lymphoblastic leukemia. Int J Mol Sci. 2021;22(4):2150.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"683_CR63","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/14737140.2017.1347507","volume":"17","author":"J Pierro","year":"2017","unstructured":"Pierro J, Hogan LE, Bhatla T, Carroll WL. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 2017;17(8):725\u201336.","journal-title":"Expert Rev Anticancer Ther"},{"key":"683_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejca.2021.10.016","volume":"160","author":"AD Pearson","year":"2022","unstructured":"Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, et al. Paediatric strategy forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European medicines agency with participation of the food and drug administration. Eur J Cancer. 2022;160:112\u201333.","journal-title":"Eur J Cancer"},{"issue":"12","key":"683_CR65","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, et al. Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell Non-Hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transpl. 2019;25(12):2305\u201321.","journal-title":"Biol Blood Marrow Transpl"},{"key":"683_CR66","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.34172\/ijhpm.8543","volume":"13","author":"SL Zheng","year":"2024","unstructured":"Zheng SL, Zhang XQ. A new Outcomes-Based payment plan from a Chinese company to improve patient affordability of CAR-T product. Int J Health Policy Manag. 2024;13:8543.","journal-title":"Int J Health Policy Manag"},{"issue":"6","key":"683_CR67","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","volume":"36","author":"B Ghanem","year":"2022","unstructured":"Ghanem B, Shi L. The economic burden of CAR T cell therapies ciltacabtagene autoleucel and Idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US. BioDrugs. 2022;36(6):773\u201380.","journal-title":"BioDrugs"},{"issue":"4","key":"683_CR68","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40291-024-00719-9","volume":"28","author":"T Nie","year":"2024","unstructured":"Nie T. Talicabtagene autoleucel: first approval. Mol Diagn Ther. 2024;28(4):495\u20139.","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"683_CR69","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771.","journal-title":"J Pers Med"},{"key":"683_CR70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.","journal-title":"Front Immunol"},{"issue":"12","key":"683_CR71","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"683_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"683_CR73","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20\u20132.","journal-title":"J Clin Oncol"},{"issue":"4","key":"683_CR74","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"issue":"6","key":"683_CR75","doi-asserted-by":"publisher","first-page":"e007162","DOI":"10.1136\/jitc-2023-007162","volume":"11","author":"S Papa","year":"2023","unstructured":"Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D, et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J Immunother Cancer. 2023;11(6):e007162.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"683_CR76","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.194.7.953","volume":"194","author":"W Weninger","year":"2001","unstructured":"Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med. 2001;194(7):953\u201366.","journal-title":"J Exp Med"},{"issue":"3","key":"683_CR77","doi-asserted-by":"publisher","first-page":"112175","DOI":"10.1016\/j.celrep.2023.112175","volume":"42","author":"CP Camargo","year":"2023","unstructured":"Camargo CP, Muhuri AK, Alapan Y, Sestito LF, Khosla M, Manspeaker MP, et al. Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8(+) T cells with enhanced tumor homing to improve cell therapy. Cell Rep. 2023;42(3):112175.","journal-title":"Cell Rep"},{"issue":"4","key":"683_CR78","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"issue":"6","key":"683_CR79","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3892\/ijo.2023.5578","volume":"63","author":"MA Kausar","year":"2023","unstructured":"Kausar MA, Anwar S, El-Horany HE, Khan FH, Tyagi N, Najm MZ, et al. Journey of CAR T\u2013cells: emphasising the concepts and advancements in breast cancer (Review). Int J Oncol. 2023;63(6):130.","journal-title":"Int J Oncol"},{"issue":"1","key":"683_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biomedicines9010059","volume":"9","author":"E Zmievskaya","year":"2021","unstructured":"Zmievskaya E, Valiullina A, Ganeeva I, Petukhov A, Rizvanov A, Bulatov E. Application of CAR-T cell therapy beyond oncology: autoimmune diseases and viral infections. Biomedicines. 2021;9(1):59.","journal-title":"Biomedicines"},{"key":"683_CR81","doi-asserted-by":"publisher","first-page":"950923","DOI":"10.3389\/fphar.2022.950923","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022;13:950923.","journal-title":"Front Pharmacol"},{"issue":"1","key":"683_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","volume":"13","author":"Y Yang","year":"2024","unstructured":"Yang Y, Peng H, Wang J, Li F. New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies. Exp Hematol Oncol. 2024;13(1):110.","journal-title":"Exp Hematol Oncol"},{"key":"683_CR83","doi-asserted-by":"publisher","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR-T cell therapy. Front Immunol. 2021;12:663201.","journal-title":"Front Immunol"},{"issue":"9","key":"683_CR84","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ajh.26259","volume":"96","author":"C Dolladille","year":"2021","unstructured":"Dolladille C, Ederhy S, Ezine E, Choquet S, Nguyen LS, Alexandre J, et al. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study. Am J Hematol. 2021;96(9):1101\u201311.","journal-title":"Am J Hematol"},{"issue":"1","key":"683_CR85","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"683_CR86","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transpl. 2021;56(3):552\u201366.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"683_CR87","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"683_CR88","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3390\/ph17081025","volume":"17","author":"Z Guo","year":"2024","unstructured":"Guo Z, Ding Y, Wang M, Zhai Q, Liu J, Du Q. Comparing the differences in adverse events among chimeric antigen receptor T-Cell therapies: A Real-World pharmacovigilance study. Pharmaceuticals (Basel). 2024;17(8):1025.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"683_CR89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl. 2020;26(5):865\u201375.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"683_CR90","doi-asserted-by":"publisher","first-page":"e2206856","DOI":"10.1002\/advs.202206856","volume":"10","author":"SW Huang","year":"2023","unstructured":"Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI, et al. BiTE-Secreting CAR-\u03b3\u03b4T as a dual targeting strategy for the treatment of solid tumors. Adv Sci (Weinh). 2023;10(17):e2206856.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"683_CR91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","volume":"73","author":"T Tachi","year":"2024","unstructured":"Tachi T, Kijima N, Kuroda H, Ikeda S, Murakami K, Nakagawa T, et al. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Cancer Immunol Immunother. 2024;73(12):256.","journal-title":"Cancer Immunol Immunother"},{"key":"683_CR92","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, et al. Current perspectives on Off-The-Shelf allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135.","journal-title":"Front Immunol"},{"issue":"3","key":"683_CR93","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"683_CR94","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461\u20139.","journal-title":"Blood"},{"key":"683_CR95","doi-asserted-by":"publisher","first-page":"1167266","DOI":"10.3389\/fonc.2023.1167266","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, Metheny L. Umbilical cord blood derived cellular therapy: advances in clinical development. Front Oncol. 2023;13:1167266.","journal-title":"Front Oncol"},{"issue":"2","key":"683_CR96","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.stem.2018.07.007","volume":"23","author":"EL Siegler","year":"2018","unstructured":"Siegler EL, Zhu Y, Wang P, Yang L. Off-the-Shelf CAR-NK cells for Cancer immunotherapy. Cell Stem Cell. 2018;23(2):160\u20131.","journal-title":"Cell Stem Cell"},{"key":"683_CR97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for Immunotherapy - Advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.","journal-title":"Front Immunol"},{"issue":"357","key":"683_CR98","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","volume":"8","author":"R Romee","year":"2016","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357ra123.","journal-title":"Sci Transl Med"},{"issue":"2","key":"683_CR99","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","volume":"19","author":"S Oelsner","year":"2017","unstructured":"Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235\u201349.","journal-title":"Cytotherapy"},{"key":"683_CR100","doi-asserted-by":"publisher","first-page":"216242","DOI":"10.1016\/j.canlet.2023.216242","volume":"566","author":"M Poorebrahim","year":"2023","unstructured":"Poorebrahim M, Quiros-Fernandez I, Marm\u00e9 F, Burdach SE, Cid-Arregui A. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. Cancer Lett. 2023;566:216242.","journal-title":"Cancer Lett"},{"issue":"2","key":"683_CR101","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells engineered with chimeric antigen receptors enhance Anti-tumor activity. Cell Stem Cell. 2018;23(2):181\u2013e925.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"683_CR102","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"683_CR103","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/cancers11060769","volume":"11","author":"KB Lupo","year":"2019","unstructured":"Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive Cancer immunotherapy. Cancers (Basel). 2019;11(6):769.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"683_CR104","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1002\/eji.201444515","volume":"44","author":"N Bhatnagar","year":"2014","unstructured":"Bhatnagar N, Ahmad F, Hong HS, Eberhard J, Lu IN, Ballmaier M, et al. Fc\u03b3RIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and Fc\u03b3RII (CD32). Eur J Immunol. 2014;44(11):3368\u201379.","journal-title":"Eur J Immunol"},{"issue":"6","key":"683_CR105","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"683_CR106","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"10","key":"683_CR107","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/leu.2017.8","volume":"31","author":"KH Chen","year":"2017","unstructured":"Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151\u201360.","journal-title":"Leukemia"},{"key":"683_CR108","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.omtm.2020.03.017","volume":"17","author":"Y Gong","year":"2020","unstructured":"Gong Y, Klein Wolterink RGJ, Janssen I, Groot AJ, Bos GMJ, Germeraad WTV. Rosuvastatin enhances VSV-G lentiviral transduction of NK cells via upregulation of the Low-Density lipoprotein receptor. Mol Ther Methods Clin Dev. 2020;17:634\u201346.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"683_CR109","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","volume":"20","author":"DSJ Allan","year":"2021","unstructured":"Allan DSJ, Chakraborty M, Waller GC, Hochman MJ, Poolcharoen A, Reger RN, et al. Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion. Mol Ther Methods Clin Dev. 2021;20:559\u201371.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"683_CR110","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","volume":"13","author":"L Egli","year":"2024","unstructured":"Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, M\u00fcnz C, et al. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp Hematol Oncol. 2024;13(1):51.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR111","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40164-024-00577-5","volume":"13","author":"Y Zu","year":"2024","unstructured":"Zu Y, Ren Q, Zhang J, Su H, Lu Q, Song Y, et al. Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies. Exp Hematol Oncol. 2024;13(1):104.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR112","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-024-00481-y","volume":"13","author":"J Shang","year":"2024","unstructured":"Shang J, Hu S, Wang X. Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):21.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR113","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024;13(1):118.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"683_CR114","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"5","key":"683_CR115","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/d41573-020-00053-9","volume":"19","author":"MT Villanueva","year":"2020","unstructured":"Villanueva MT. Macrophages get a CAR. Nat Rev Drug Discov. 2020;19(5):308.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"683_CR116","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J Immunol. 2000;164(12):6166\u201373.","journal-title":"J Immunol"},{"issue":"8","key":"683_CR117","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"683_CR118","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2024.05.006","volume":"31","author":"D Paasch","year":"2024","unstructured":"Paasch D, Lachmann N. CAR macrophages tuning the immune symphony of anti-cancer therapies. Cell Stem Cell. 2024;31(6):791\u20133.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"683_CR119","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"issue":"14","key":"683_CR120","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.7150\/thno.98290","volume":"14","author":"F Feng","year":"2024","unstructured":"Feng F, Shen J, Qi Q, Zhang Y, Ni S. Empowering brain tumor management: chimeric antigen receptor macrophage therapy. Theranostics. 2024;14(14):5725\u201342.","journal-title":"Theranostics"},{"key":"683_CR121","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688","volume":"7","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. Elife. 2018;7:e36688.","journal-title":"Elife"},{"issue":"10","key":"683_CR122","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121(10):837\u201345.","journal-title":"Br J Cancer"},{"issue":"1","key":"683_CR123","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Taremi S, Heidari M, Esmaeilzadeh A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark Res. 2023;11(1):103.","journal-title":"Biomark Res"},{"issue":"1","key":"683_CR124","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"683_CR125","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31(4):1171\u201382.","journal-title":"Nat Med"},{"issue":"1","key":"683_CR126","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.","journal-title":"Mol Cancer"},{"issue":"19","key":"683_CR127","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.7150\/thno.101941","volume":"14","author":"R Lv","year":"2024","unstructured":"Lv R, Guo Y, Liu W, Dong G, Liu X, Li C, et al. Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy. Theranostics. 2024;14(19):7424\u201347.","journal-title":"Theranostics"},{"issue":"1","key":"683_CR128","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23(1):86.","journal-title":"Cancer Cell Int"},{"issue":"21","key":"683_CR129","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"F Simonetta","year":"2021","unstructured":"Simonetta F, Lohmeyer JK, Hirai T, Maas-Bauer K, Alvarez M, Wenokur AS, et al. Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-Cell Cross-Priming. Clin Cancer Res. 2021;27(21):6054\u201364.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"683_CR130","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124(18):2824\u201333.","journal-title":"Blood"},{"issue":"3","key":"683_CR131","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41573-019-0038-z","volume":"19","author":"Z Sebestyen","year":"2020","unstructured":"Sebestyen Z, Prinz I, D\u00e9chanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19(3):169\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"683_CR132","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"4","key":"683_CR133","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05077.x","volume":"126","author":"M Rischer","year":"2004","unstructured":"Rischer M, Pscherer S, Duwe S, Vormoor J, J\u00fcrgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126(4):583\u201392.","journal-title":"Br J Haematol"},{"issue":"12","key":"683_CR134","doi-asserted-by":"publisher","first-page":"100473","DOI":"10.1016\/j.xcrm.2021.100473","volume":"2","author":"RE Beatson","year":"2021","unstructured":"Beatson RE, Parente-Pereira AC, Halim L, Cozzetto D, Hull C, Whilding LM, et al. TGF-\u03b21 potentiates V\u03b39V\u03b42 T cell adoptive immunotherapy of cancer. Cell Rep Med. 2021;2(12):100473.","journal-title":"Cell Rep Med"},{"key":"683_CR135","doi-asserted-by":"publisher","first-page":"1491282","DOI":"10.3389\/fcell.2024.1491282","volume":"12","author":"M Alidadi","year":"2024","unstructured":"Alidadi M, Barzgar H, Zaman M, Paevskaya OA, Metanat Y, Khodabandehloo E, et al. Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects. Front Cell Dev Biol. 2024;12:1491282.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"683_CR136","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1038\/s41598-019-49818-2","volume":"9","author":"S In","year":"2019","unstructured":"In S, Yook N, Kim JH, Shin M, Tak S, Jeon JH, et al. Enhancement of exfoliating efficacy of L-carnitine with ion-pair method monitored by nuclear magnetic resonance spectroscopy. Sci Rep. 2019;9(1):13507.","journal-title":"Sci Rep"},{"key":"683_CR137","doi-asserted-by":"publisher","first-page":"1187665","DOI":"10.3389\/fimmu.2023.1187665","volume":"14","author":"M Ib\u00e1\u00f1ez-Navarro","year":"2023","unstructured":"Ib\u00e1\u00f1ez-Navarro M, Fern\u00e1ndez A, Escudero A, Esteso G, Campos-Silva C, Navarro-Aguadero M\u00c1, et al. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells. Front Immunol. 2023;14:1187665.","journal-title":"Front Immunol"},{"key":"683_CR138","doi-asserted-by":"publisher","first-page":"1235222","DOI":"10.3389\/fimmu.2023.1235222","volume":"14","author":"CD Moorman","year":"2023","unstructured":"Moorman CD, Yu S, Briseno CG, Phee H, Sahoo A, Ramrakhiani A, et al. CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis. Front Immunol. 2023;14:1235222.","journal-title":"Front Immunol"},{"issue":"22","key":"683_CR139","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, et al. CAR-Macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells. 2022;11(22):3692.","journal-title":"Cells"},{"issue":"19\u201320","key":"683_CR140","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1089\/hum.2021.173","volume":"32","author":"M Irving","year":"2021","unstructured":"Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen Receptor-T cells. Hum Gene Ther. 2021;32(19\u201320):1044\u201358.","journal-title":"Hum Gene Ther"},{"key":"683_CR141","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"P Prazeres","year":"2023","unstructured":"Prazeres P, Ferreira H, Costa PAC, da Silva W, Alves MT, Padilla M, et al. Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells. Int J Nanomed. 2023;18:5891\u2013904.","journal-title":"Int J Nanomed"},{"issue":"13","key":"683_CR142","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1021\/acs.nanolett.1c01353","volume":"21","author":"SJ Shepherd","year":"2021","unstructured":"Shepherd SJ, Warzecha CC, Yadavali S, El-Mayta R, Alameh MG, Wang L, et al. Scalable mRNA and SiRNA lipid nanoparticle production using a parallelized microfluidic device. Nano Lett. 2021;21(13):5671\u201380.","journal-title":"Nano Lett"},{"issue":"1","key":"683_CR143","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8(1):149.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"683_CR144","doi-asserted-by":"publisher","first-page":"eabf1333","DOI":"10.1126\/sciadv.abf1333","volume":"7","author":"M Bozza","year":"2021","unstructured":"Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of Recombinant T cells. Sci Adv. 2021;7(16):eabf1333.","journal-title":"Sci Adv"},{"issue":"1","key":"683_CR145","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40164-024-00584-6","volume":"13","author":"H Zheng","year":"2024","unstructured":"Zheng H, Zhao H, Han S, Kong D, Zhang Q, Zhang M, et al. Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies. Exp Hematol Oncol. 2024;13(1):117.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"683_CR146","doi-asserted-by":"publisher","first-page":"e2300665","DOI":"10.1002\/adma.202300665","volume":"36","author":"K Yi","year":"2024","unstructured":"Yi K, Kong H, Lao YH, Li D, Mintz RL, Fang T, et al. Engineered nanomaterials to potentiate CRISPR\/Cas9 gene editing for Cancer therapy. Adv Mater. 2024;36(13):e2300665.","journal-title":"Adv Mater"},{"key":"683_CR147","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/ITT.S474659","volume":"13","author":"S Srivastava","year":"2024","unstructured":"Srivastava S, Tyagi A, Pawar VA, Khan NH, Arora K, Verma C, et al. Revolutionizing immunotherapy: unveiling new horizons, confronting challenges, and navigating therapeutic frontiers in CAR-T Cell-Based gene therapies. Immunotargets Ther. 2024;13:413\u201333.","journal-title":"Immunotargets Ther"},{"issue":"3","key":"683_CR148","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/crispr.2022.0089","volume":"6","author":"RC Lamothe","year":"2023","unstructured":"Lamothe RC, Storlie MD, Espinosa DA, Rudlaff R, Browne P, Liu J, et al. Novel CRISPR-Associated Gene-Editing systems discovered in metagenomic samples enable efficient and specific genome engineering. Crispr J. 2023;6(3):243\u201360.","journal-title":"Crispr J"},{"issue":"1","key":"683_CR149","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40164-024-00545-z","volume":"13","author":"J Hu","year":"2024","unstructured":"Hu J, Zhong L, Wang Y, Hu S, Zhang L, Tian Q. Cell membrane patches transfer CAR molecules from a cellular depot to conventional T cells for constructing innovative fused-CAR-T cells without necessitating genetic modification. Exp Hematol Oncol. 2024;13(1):75.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"683_CR150","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich A, Thomas M, Gr\u00fcnmeier R, Lesch S, Rohrbacher L, Igl V, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023;41(11):1618\u201332.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"683_CR151","doi-asserted-by":"publisher","first-page":"e006007","DOI":"10.1136\/jitc-2022-006007","volume":"11","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023;11(2):e006007.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"683_CR152","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40164-024-00542-2","volume":"13","author":"X Gu","year":"2024","unstructured":"Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. 2024;13(1):70.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"683_CR153","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling cars: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66.","journal-title":"Exp Hematol Oncol"},{"key":"683_CR154","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266.","journal-title":"EBioMedicine"},{"issue":"2","key":"683_CR155","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"HK Palani","year":"2023","unstructured":"Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA, et al. Decentralized manufacturing of anti CD19 CAR-T cells using clinimacs Prodigy\u00ae: real-world experience and cost analysis in India. Bone Marrow Transpl. 2023;58(2):160\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"683_CR156","doi-asserted-by":"publisher","first-page":"200889","DOI":"10.1016\/j.omton.2024.200889","volume":"32","author":"S Luanpitpong","year":"2024","unstructured":"Luanpitpong S, Klaihmon P, Janan M, Kungwankiattichai S, Owattanapanich W, Kunacheewa C, et al. Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: experiences of an academic in Thailand. Mol Ther Oncol. 2024;32(4):200889.","journal-title":"Mol Ther Oncol"},{"issue":"12","key":"683_CR157","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41587-023-01981-8","volume":"41","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Maus MV. Expanding access to CAR T cell therapies through local manufacturing. Nat Biotechnol. 2023;41(12):1698\u2013708.","journal-title":"Nat Biotechnol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00683-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00683-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T15:03:00Z","timestamp":1751468580000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00683-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00683-y","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}